Qiang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qiang Zhang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ning Kang
State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
8 shared publications - Feng Qiu
School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China
5 shared publications Chengpeng Sun
School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China
2 shared publicationsQiuju Zhang
School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
2 shared publications- Shijie Cao
State Key Laboratory of Component‐based Chinese Medicine Tianjin University of Traditional Chinese Medicine Tianjin People's Republic of China
2 shared publications Tiancheng Zhan
School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
2 shared publications
Latest Publications
- 20 May 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (6) , 1915-1933
Targeting VAMPs in Aging-Related Diseases: From Mechanisms to Pharmacotherapy
Vesicle-associated membrane proteins (VAMPs) are key regulators of membrane fusion, vesicular trafficking and intercellular communication. Structurally and functionally diverse, VAMPs participate in multiple physiological processes, and their dysfunction facilitates the progression of various aging-related diseases. This review aims to systematically summarize the molecular mechanisms and therapeutic potential of VAMPs. We summarize current evidence to clarify the functions of VAMPs in aging-related disorders, and elaborate their roles in vesicle dynamic events as well as the regulatory effects of post-translational modifications on VAMP activity. VAMPs are closely involved in neurodegenerative, metabolic, cardiovascular diseases and cancers. They modulate the whole process of vesicle circulation, and post-translational modifications dynamically regulate VAMP function. VAMP-targeting agents present promising prospects for disease intervention. Targeting VAMPs provides innovative therapeutic strategies to ameliorate aging-related pathological conditions.
- 20 May 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (6) , 1915-1933
Targeting VAMPs in Aging-Related Diseases: From Mechanisms to Pharmacotherapy
Vesicle-associated membrane proteins (VAMPs) are key regulators of membrane fusion, vesicular trafficking and intercellular communication. Structurally and functionally diverse, VAMPs participate in multiple physiological processes, and their dysfunction facilitates the progression of various aging-related diseases. This review aims to systematically summarize the molecular mechanisms and therapeutic potential of VAMPs. We summarize current evidence to clarify the functions of VAMPs in aging-related disorders, and elaborate their roles in vesicle dynamic events as well as the regulatory effects of post-translational modifications on VAMP activity. VAMPs are closely involved in neurodegenerative, metabolic, cardiovascular diseases and cancers. They modulate the whole process of vesicle circulation, and post-translational modifications dynamically regulate VAMP function. VAMP-targeting agents present promising prospects for disease intervention. Targeting VAMPs provides innovative therapeutic strategies to ameliorate aging-related pathological conditions.
- 21 April 2026
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 45 (1-3) , 78-112
Redox-Encoded Proteostasis: Heat Shock Proteins as Integrators of Stress Adaptation and Therapeutic Targets
Significance: Cellular proteostasis is essential for cellular proteome integrity, which is exquisitely sensitive to the redox environment. Heat shock proteins (HSPs) are the central chaperones that sense and adapt to these redox fluctuations. Emerging evidence demonstrates dysregulation of cellular HSPs-modulated redox-proteostasis in protein aggregation diseases, including cancers, senescence, neurodegenerative diseases, limb-girdle muscular dystrophy type D1, and β-thalassemia, making HSPs promising therapeutic targets in disease treatment. Recent Advances: Redox post-translational modifications (PTMs) serve as master switchboards to dynamically modulate the structure and chaperone function of HSPs. Redox PTMs allow HSPs to participate in protein synthesis and folding, conformational maintenance, and degradation, thereby maintaining cellular proteostasis. Beyond their chaperone functions, HSPs also play critical roles in organelle-specific stress responses, such as mitochondrial unfolded protein response, endoplasmic reticulum (ER) stress, and unfolded protein response. Critical Issues: Despite the well-known contributions of HSPs to redox-proteostasis, the double-edged functions of HSPs in protein aggregation diseases remain unclear. The main issues covered in this review include the regulation of HSPs by redox PTMs, the important role of HSPs in proteostasis and organelle-specific stress responses, dual modulation of HSPs in protein aggregation diseases, and pharmacological agents targeting HSPs. Further Directions: The functional diversity of HSPs in redox-proteostasis makes them promising therapeutic targets in disease treatment. Further studies should focus on exploiting agents that precisely target cysteine residues modifications on HSPs with good blood–brain barrier (BBB) penetration and low toxicity. Antioxid. Redox Signal. 45, 78–112.
- 21 April 2026
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 45 (1-3) , 78-112
Redox-Encoded Proteostasis: Heat Shock Proteins as Integrators of Stress Adaptation and Therapeutic Targets
Significance: Cellular proteostasis is essential for cellular proteome integrity, which is exquisitely sensitive to the redox environment. Heat shock proteins (HSPs) are the central chaperones that sense and adapt to these redox fluctuations. Emerging evidence demonstrates dysregulation of cellular HSPs-modulated redox-proteostasis in protein aggregation diseases, including cancers, senescence, neurodegenerative diseases, limb-girdle muscular dystrophy type D1, and β-thalassemia, making HSPs promising therapeutic targets in disease treatment. Recent Advances: Redox post-translational modifications (PTMs) serve as master switchboards to dynamically modulate the structure and chaperone function of HSPs. Redox PTMs allow HSPs to participate in protein synthesis and folding, conformational maintenance, and degradation, thereby maintaining cellular proteostasis. Beyond their chaperone functions, HSPs also play critical roles in organelle-specific stress responses, such as mitochondrial unfolded protein response, endoplasmic reticulum (ER) stress, and unfolded protein response. Critical Issues: Despite the well-known contributions of HSPs to redox-proteostasis, the double-edged functions of HSPs in protein aggregation diseases remain unclear. The main issues covered in this review include the regulation of HSPs by redox PTMs, the important role of HSPs in proteostasis and organelle-specific stress responses, dual modulation of HSPs in protein aggregation diseases, and pharmacological agents targeting HSPs. Further Directions: The functional diversity of HSPs in redox-proteostasis makes them promising therapeutic targets in disease treatment. Further studies should focus on exploiting agents that precisely target cysteine residues modifications on HSPs with good blood–brain barrier (BBB) penetration and low toxicity. Antioxid. Redox Signal. 45, 78–112.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 26 (1) , 1-16
Targeting SERCA2 in Anti-Tumor Drug Discovery
SERCA2, a P-type ATPase located on the endoplasmic reticulum of cells, plays an important role in maintaining calcium balance within cells by transporting calcium from the cytoplasm to the endoplasmic reticulum against its concentration gradient. A multitude of studies have demonstrated that the expression of SERCA2 is abnormal in a wide variety of tumor cells. Consequently, research exploring compounds that target SERCA2 may offer a promising avenue for the development of novel anti-tumor drugs. This review has summarized the anti-tumor compounds targeting SERCA2, including thapsigargin, dihydroartemisinin, curcumin, galangin, etc. These compounds interact with SERCA2 on the endoplasmic reticulum membrane, disrupting intracellular calcium ion homeostasis, leading to tumor cell apoptosis, autophagy and cell cycle arrest, ultimately producing anti-tumor effects. Additionally, several potential research directions for compounds targeting SERCA2 as clinical anti-cancer drugs have been proposed in the review. In summary, SERCA2 is a promising anti-tumor target for drug discovery and development.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 26 (1) , 1-16
Targeting SERCA2 in Anti-Tumor Drug Discovery
SERCA2, a P-type ATPase located on the endoplasmic reticulum of cells, plays an important role in maintaining calcium balance within cells by transporting calcium from the cytoplasm to the endoplasmic reticulum against its concentration gradient. A multitude of studies have demonstrated that the expression of SERCA2 is abnormal in a wide variety of tumor cells. Consequently, research exploring compounds that target SERCA2 may offer a promising avenue for the development of novel anti-tumor drugs. This review has summarized the anti-tumor compounds targeting SERCA2, including thapsigargin, dihydroartemisinin, curcumin, galangin, etc. These compounds interact with SERCA2 on the endoplasmic reticulum membrane, disrupting intracellular calcium ion homeostasis, leading to tumor cell apoptosis, autophagy and cell cycle arrest, ultimately producing anti-tumor effects. Additionally, several potential research directions for compounds targeting SERCA2 as clinical anti-cancer drugs have been proposed in the review. In summary, SERCA2 is a promising anti-tumor target for drug discovery and development.
- Open Access
- 4 November 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 75, 591-605
Tetrahydrocurcumin targets TRIP13 inhibiting the interaction of TRIP13/USP7/c-FLIP to mediate c-FLIP ubiquitination in triple-negative breast cancer
- 4 November 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 75, 591-605
Open AccessTetrahydrocurcumin targets TRIP13 inhibiting the interaction of TRIP13/USP7/c-FLIP to mediate c-FLIP ubiquitination in triple-negative breast cancer
- 29 May 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 977, 176681
Targeting TRPs in autophagy regulation and human diseases
- 29 May 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 977, 176681
Targeting TRPs in autophagy regulation and human diseases
- 21 March 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (8) , 1807-1835
Zebrafish live imaging: a strong weapon in anticancer drug discovery and development
Developing anticancer drugs is a complex and time-consuming process. The inability of current laboratory models to reflect important aspects of the tumor in vivo limits anticancer medication research. Zebrafish is a rapid, semi-automated in vivo screening platform that enables the use of non-invasive imaging methods to monitor morphology, survival, developmental status, response to drugs, locomotion, or other behaviors. Zebrafish models are widely used in drug discovery and development for anticancer drugs, especially in conjunction with live imaging techniques. Herein, we concentrated on the use of zebrafish live imaging in anticancer therapeutic research, including drug screening, efficacy assessment, toxicity assessment, and mechanism studies. Zebrafish live imaging techniques have been used in numerous studies, but this is the first time that these techniques have been comprehensively summarized and compared side by side. Finally, we discuss the hypothesis of Zebrafish Composite Model, which may provide future directions for zebrafish imaging in the field of cancer research.
- 21 March 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (8) , 1807-1835
Zebrafish live imaging: a strong weapon in anticancer drug discovery and development
Developing anticancer drugs is a complex and time-consuming process. The inability of current laboratory models to reflect important aspects of the tumor in vivo limits anticancer medication research. Zebrafish is a rapid, semi-automated in vivo screening platform that enables the use of non-invasive imaging methods to monitor morphology, survival, developmental status, response to drugs, locomotion, or other behaviors. Zebrafish models are widely used in drug discovery and development for anticancer drugs, especially in conjunction with live imaging techniques. Herein, we concentrated on the use of zebrafish live imaging in anticancer therapeutic research, including drug screening, efficacy assessment, toxicity assessment, and mechanism studies. Zebrafish live imaging techniques have been used in numerous studies, but this is the first time that these techniques have been comprehensively summarized and compared side by side. Finally, we discuss the hypothesis of Zebrafish Composite Model, which may provide future directions for zebrafish imaging in the field of cancer research.
- 4 January 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (2) , 1104-1158
Withanolides: Promising candidates for cancer therapy
Natural products have played a significant role throughout history in the prevention and treatment of numerous diseases, particularly cancers. As a natural product primarily derived from various medicinal plants in the Withania genus, withanolides have been shown in several studies to exhibit potential activities in cancer treatment. Consequently, understanding the molecular mechanism of withanolides could herald the discovery of new anticancer agents. Withanolides have been studied widely, especially in the last 20 years, and attracted the attention of numerous researchers. Currently, over 1200 withanolides have been classified, with approximately a quarter of them having been reported in the literature to be able to modulate the survival and death of cancer cells through multiple avenues. To what extent, though, has the anticancer effects of these compounds been studied? How far are they from being developed into clinical drugs? What are their potential, characteristic features, and challenges? In this review, we elaborate on the current knowledge of natural compounds belonging to this class and provide an overview of their natural sources, anticancer activity, mechanism of action, molecular targets, and implications for anticancer drug research. In addition, direct targets and clinical research to guide the design and implementation of future preclinical and clinical studies to accelerate the application of withanolides have been highlighted.
- 4 January 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (2) , 1104-1158
Withanolides: Promising candidates for cancer therapy
Natural products have played a significant role throughout history in the prevention and treatment of numerous diseases, particularly cancers. As a natural product primarily derived from various medicinal plants in the Withania genus, withanolides have been shown in several studies to exhibit potential activities in cancer treatment. Consequently, understanding the molecular mechanism of withanolides could herald the discovery of new anticancer agents. Withanolides have been studied widely, especially in the last 20 years, and attracted the attention of numerous researchers. Currently, over 1200 withanolides have been classified, with approximately a quarter of them having been reported in the literature to be able to modulate the survival and death of cancer cells through multiple avenues. To what extent, though, has the anticancer effects of these compounds been studied? How far are they from being developed into clinical drugs? What are their potential, characteristic features, and challenges? In this review, we elaborate on the current knowledge of natural compounds belonging to this class and provide an overview of their natural sources, anticancer activity, mechanism of action, molecular targets, and implications for anticancer drug research. In addition, direct targets and clinical research to guide the design and implementation of future preclinical and clinical studies to accelerate the application of withanolides have been highlighted.
- 11 March 2022
- Published by Wiley in Medicinal Research Reviews
- Vol. 42 (4) , 1545-1587
Incomplete autophagy: Trouble is a friend
Incomplete autophagy is an impaired self‐eating process of intracellular macromolecules and organelles in which accumulated autophagosomes do not fuse with lysosomes for degradation, resulting in the blockage of autophagic flux. In this review, we summarized the literature over the past decade describing incomplete autophagy, and found that different from the double‐edged sword effect of general autophagy on promoting cell survival or death, incomplete autophagy plays a crucial role in disrupting cellular homeostasis, and promotes only cell death. What matters is that incomplete autophagy is closely relevant to the pathogenesis and progression of various human diseases, which, meanwhile, intimately linking to the pharmacologic and toxicologic effects of several compounds. Here, we comprehensively reviewed the latest progress of incomplete autophagy on molecular mechanisms and signaling pathways. Moreover, implications of incomplete autophagy for pharmacotherapy are also discussed, which has great relevance for our understanding of the distinctive role of incomplete autophagy in cellular physiology and disease. Consequently, targeting incomplete autophagy may contribute to the development of novel generation therapeutic agents for diverse human diseases.
- 11 March 2022
- Published by Wiley in Medicinal Research Reviews
- Vol. 42 (4) , 1545-1587
Incomplete autophagy: Trouble is a friend
Incomplete autophagy is an impaired self‐eating process of intracellular macromolecules and organelles in which accumulated autophagosomes do not fuse with lysosomes for degradation, resulting in the blockage of autophagic flux. In this review, we summarized the literature over the past decade describing incomplete autophagy, and found that different from the double‐edged sword effect of general autophagy on promoting cell survival or death, incomplete autophagy plays a crucial role in disrupting cellular homeostasis, and promotes only cell death. What matters is that incomplete autophagy is closely relevant to the pathogenesis and progression of various human diseases, which, meanwhile, intimately linking to the pharmacologic and toxicologic effects of several compounds. Here, we comprehensively reviewed the latest progress of incomplete autophagy on molecular mechanisms and signaling pathways. Moreover, implications of incomplete autophagy for pharmacotherapy are also discussed, which has great relevance for our understanding of the distinctive role of incomplete autophagy in cellular physiology and disease. Consequently, targeting incomplete autophagy may contribute to the development of novel generation therapeutic agents for diverse human diseases.
- Open Access
S5, a Withanolide Isolated from Physalis Pubescens L., Induces G2/M Cell Cycle Arrest via the EGFR/P38 Pathway in Human Melanoma A375 Cells
S5 is a withanolide natural product isolated from Physalis pubescens L. Our previous experimental studies found that it has significant antitumor activity on renal cell carcinoma. In the present study, the anti-melanoma effect of S5 and the related molecular mechanism was first investigated. It was found that S5 induced an obvious growth inhibitory effect on human melanoma A375 cells with low toxicity to human peripheral blood cells. Furthermore, the results demonstrated that the cell death mode of S5 on A375 cells is not due to inducing apoptosis and autophagy. However, there was a significant time-dependent increase in G2/M phase after treatment of A375 with S5. Meanwhile, S5 could also decrease the protein expression of Cdc25c, Cdc2, and CyclinB1, and increased the expression of p-P53 and P21, suggesting that S5 inhibited A375 cell death through G2/M phase arrest. Moreover, the signal pathway factors P38, extracellular regulated protein kinases (ERK), and epidermal growth factor receptor (EGFR) were observed taking part in the S5-induced A375 cells growth inhibitory effect. In addition, suppressing P38 and EGFR reversed the cell proliferation inhibitory effect and G2/M cell cycle arrest induced by S5 and inhibition of EGFR enhanced the downregulation of the expression of P38 and p-P38, indicating that S5 induced A375 G2/M arrest through the EGFR/P38 pathway. Briefly, this study explained for the first time the mechanism of S5-induced A375 cell growth inhibition in order to provide the basis for its clinical application in melanoma.
Open AccessS5, a Withanolide Isolated from Physalis Pubescens L., Induces G2/M Cell Cycle Arrest via the EGFR/P38 Pathway in Human Melanoma A375 Cells
S5 is a withanolide natural product isolated from Physalis pubescens L. Our previous experimental studies found that it has significant antitumor activity on renal cell carcinoma. In the present study, the anti-melanoma effect of S5 and the related molecular mechanism was first investigated. It was found that S5 induced an obvious growth inhibitory effect on human melanoma A375 cells with low toxicity to human peripheral blood cells. Furthermore, the results demonstrated that the cell death mode of S5 on A375 cells is not due to inducing apoptosis and autophagy. However, there was a significant time-dependent increase in G2/M phase after treatment of A375 with S5. Meanwhile, S5 could also decrease the protein expression of Cdc25c, Cdc2, and CyclinB1, and increased the expression of p-P53 and P21, suggesting that S5 inhibited A375 cell death through G2/M phase arrest. Moreover, the signal pathway factors P38, extracellular regulated protein kinases (ERK), and epidermal growth factor receptor (EGFR) were observed taking part in the S5-induced A375 cells growth inhibitory effect. In addition, suppressing P38 and EGFR reversed the cell proliferation inhibitory effect and G2/M cell cycle arrest induced by S5 and inhibition of EGFR enhanced the downregulation of the expression of P38 and p-P38, indicating that S5 induced A375 G2/M arrest through the EGFR/P38 pathway. Briefly, this study explained for the first time the mechanism of S5-induced A375 cell growth inhibition in order to provide the basis for its clinical application in melanoma.